PhaseBio Overview

  • Founded
  • 2002
Founded
  • Status
  • Public
  • Employees
  • 60
Employees
  • Stock Symbol
  • PHAS
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $2.24
  • (As of Friday Closing)

PhaseBio General Information

Description

PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.

Contact Information

Formerly Known As
Phase Bioscience
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • One Great Valley Parkway
  • Suite 30
  • Malvern, PA 19355
  • United States
+1 (610) 000-0000

PhaseBio Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PhaseBio Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.24 $2.23 $1.83 - $5.83 $108M 48.1M 625K -$3.10

PhaseBio Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 96,195 74,889 105,537 184,468
Revenue 10,993 320 2,361 668
EBITDA (114,133) (96,849) (39,553) (20,204)
Net Income (118,336) (98,565) (39,247) (23,846)
Total Assets 77,725 50,357 82,494 63,026
Total Debt 9,784 14,135 16,477 7,500
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PhaseBio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PhaseBio‘s full profile, request access.

Request a free trial

PhaseBio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore PhaseBio‘s full profile, request access.

Request a free trial

PhaseBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercializat
Drug Delivery
Malvern, PA
60 As of 2021
00000
00000000 00000

00000 00

cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cul
0000 00000000
Vancouver, Canada
0 As of 0000
00.00
00000000000 00.00

00000000

od tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercit
0000000000000
Mechelen, Belgium
0000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PhaseBio Competitors (81)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sitka Biopharma Venture Capital-Backed Vancouver, Canada 0 00.00 00000000000 00.00
000000000 (0000000 Formerly VC-backed Mechelen, Belgium 0000 00.000 000000000 00.000
00000 000000000000 Venture Capital-Backed Paris, France 00 000.00 00000000000 000.00
00000 000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
You’re viewing 5 of 81 competitors. Get the full list »

PhaseBio Patents

PhaseBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3452021-A4 Elp fusion proteins for controlled and sustained release Pending 06-May-2016 000000000 0
AU-2017261216-A1 Elp fusion proteins for controlled and sustained release Pending 06-May-2016 000000000
JP-2019514949-A Elp fusion protein for controlled sustained release Pending 06-May-2016 000000000
CA-3021644-A1 Elp fusion proteins for controlled and sustained release Pending 06-May-2016 0000000000
US-20190218274-A1 Elp fusion proteins for controlled and sustained release Pending 06-May-2016 C07K14/78
To view PhaseBio’s complete patent history, request access »

PhaseBio Executive Team (14)

Name Title Board Seat Contact Info
Jonathan Mow Chief Executive Officer & Board Member
John Sharp Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Jonathan Birchall Chief Commercial Officer
Michael York Vice President
Susan Arnold Ph.D Vice President
You’re viewing 5 of 14 executive team members. Get the full list »

PhaseBio Board Members (24)

Name Representing Role Since
Alex Sapir PhaseBio Board Member 000 0000
Ashutosh Chilkoti Ph.D Self Co-Founder and Board Member 000 0000
Caroline Loewy Self Board Member 000 0000
Clay Thorp Self Chairman & Founder 000 0000
Donald Dwyer AstraZeneca Board Observer 000 0000
You’re viewing 5 of 24 board members. Get the full list »

PhaseBio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PhaseBio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PhaseBio‘s full profile, request access.

Request a free trial

PhaseBio Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 13-Jan-2020 000000000 00000 Buildings and Property 00000000
ImmunoForge 01-Mar-2019 Later Stage VC 00.000 Drug Discovery
To view PhaseBio’s complete investments history, request access »